Curated clinical source

NF1-mutant melanoma

What to ask when melanoma testing reports an NF1 mutation.

NF1-mutant melanoma is a reason to ask how the oncology team interprets the genomic report. It may shape trial-search language even when it does not point to a simple standard targeted option.

What to clarify

• Was NF1 the main reported alteration or one of several findings?
• Were BRAF, NRAS, KIT, and NTRK also evaluated?
• Does the report mention tumor mutational burden or other immunotherapy-relevant features?

Questions to ask

• Does the NF1 result change treatment sequencing?
• Are there trials that include NF1-mutant or RAS-pathway melanoma?
• Should the genomic report be reviewed by a molecular tumor board?